OOIR: Observatory of International Research

Papers

(The H4-Index of Lung Cancer is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer	95
HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer	92
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer	82
Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma	58
Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers	57
HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours	57
Sarcopenia is not a useful prognostic biomarker in metastatic NSCLC patients treated with first-line pembrolizumab	55
Stereotactic ablative radiotherapy (SABR) for primary lung malignancy: a regional analysis of survival and recurrence outcomes amongst an elderly cohort	50
Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study	49
Real-world use of nivolumab plus ipilimumab in the management of diffuse pleural mesothelioma (DPM): experience from the county of Kent	49
Does consolidation radiotherapy to chest improve survival in extensive stage small cell lung cancer in the immunotherapy era? A retrospective study	48
Direct to CT screening pilot for patients with COPD in a deprived area: longitudinal analysis of the pulmonary nodule cohort outcomes	47
Prediction of next generation sequencing test failure in lung adenocarcinoma in a genomic laboratory hub setting	46
The role of mediastinoscopy following EBUS	45
Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma	44
Author index	42
Indwelling pleural catheter infections: a cautionary tale	42
Antimuscarinics and lung cancer survival: A Norwegian population-based cohort study	42
Clinical relevance of circulating activin A and follistatin in small cell lung cancer	41
Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study	41
The first historical description of malignant mesotheliomas	41
Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma: The importance of the lepidic proportion	40
Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer	40
190 Localised non-small cell lung cancer: patient characteristics and radical radiotherapy outcomes according to KRAS mutation status	38
175 External Validation of a Left Anterior Descending Coronary Artery Dose Constraint in Patients with Non-Small Cell Lung Cancer: An NI–HEART Analysis	38

107 Osimertinib Efficacy in Advanced NSCLC Patients with PACC and Classical-Like EGFR Mutations: A Retrospective Analysis from The Christie	35
101 Treating advanced EGFR positive non-small cell lung cancer patients with Osimertinib - the University Hospital Plymouth experience	35
98 Hospitalisation Rates following Systemic Anti-Cancer Treatments for Patients with Non-Small Cell Lung Cancer	34
89 Why do almost half of our patients not complete 12 months of maintenance durvalumab after successful radical chemoradiotherapy?	32
86 Real World Outcomes of Patients Receiving Neoadjuvant Treatment for Non-Small Cell Lung Cancer	32
74 The first-in-class PRX3 inhibitor RSO-021 modulates the composition of malignant pleural effusions by eliciting immunomodulation and decreasing epithelial to mesenchymal protein expression	32
Title Page	31
251 Optimising engagement and addressing inequalities for patients using a Digital Behaviour Change Intervention in lung cancer prehabilitation: A mixed-methods study	31